Characteristics and outcome of Pediatric Renal Cell Carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001, and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group
Menée à partir de données internationales sur la période 1993-2019, cette étude analyse les caractéristiques des patients pédiatriques atteints d'un carcinome à cellules rénales ainsi que la survie sans événément et la survie globale associées
In children, renal cell carcinoma (RCC) is rare. This study is the first report of pediatric patients with RCC registered by the International Society of Pediatric Oncology-Renal Tumor Study Group (SIOP-RTSG). Pediatric patients with histologically confirmed RCC, registered in SIOP 93-01, 2001, and UK-IMPORT databases, were included. Event-free survival (EFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Between 1993-2019, 122 pediatric patients with RCC were registered. Available detailed data (n=111) revealed 56 localized, 30 regionally advanced, 25 metastatic, and no bilateral cases. Histological classification according to WHO 2004, including immunohistochemical and molecular testing for transcription factor E3 (TFE3) and/or EB (TFEB) translocation, was available for 65/122 patients. In this group, the most common histological subtypes were translocation type RCC (MiT-RCC) (36/64, 56.3%), papillary type (19/64, 29.7%), and clear cell type (4/64, 6.3%). One histological subtype was not reported. In the remaining 57 patients, translocation testing could not be performed, or TFE-cytogenetics and/or immunohistochemistry results were missing. In this group the most common RCC histological subtypes were papillary type (21/47, 44.7%) and clear cell type (11/47, 23.4%). Ten histological subtypes were not reported. Estimated 5-year (5y) EFS and 5yOS of the total group was 70.5% (95%CI:61.7-80.6%) and 84.5% (95%CI:77.5-92.2%), respectively. Estimated 5yOS for localized, regionally advanced, and metastatic disease was 96.8%, 92.3%, and 45.6%, respectively. In conclusion, the registered pediatric patients with RCC showed a reasonable outcome. Survival was substantially lower for patients with metastatic disease. This descriptive study stresses the importance of full, prospective registration including TFE-testing. This article is protected by copyright. All rights reserved.